Genetic polymorphism of aldehyde dehydrogenase 2 (ALDH2) is associated with atrial fibrillation risk and atrial fibrillation recurrence after radiofrequency ablation in Chinese

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100051953

Enrollment

Unknown

Registered

2021-10-10

Start date

2021-07-20

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Interventions

atrial fibrillation :null

control:null

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Atrial fibrillation group: (1) Patients with atrial fibrillation confirmed by electrocardiogram or 24h Holter; (2) Agreed to undergo radiofrequency ablation for atrial fibrillation; (3) Agreed to sign the informed consent form for this study. Control group: (1) Patients treated with the cardiology department of our hospital; (2) Agreed to sign the informed consent form for this study.

Exclusion criteria

Exclusion criteria: Atrial fibrillation group: (1) Aged < 18 years; (2) Patients with thrombus in left atrial appendage confirmed by preoperative TEE or CCT; (3) Patients with stroke in recent 3 months; (4) Patients with severe heart failure (NYHA IV), severe chronic obstructive pulmonary disease, valvular heart disease, etc.. Control group: (1) Aged < 18 years; (2) Patients with atrial fibrillation confirmed by electrocardiogram or 24h Holter; (3) Patients with severe heart failure (NYHA IV) and valvular heart disease, etc.

Design outcomes

Primary

Measure	Time frame
ALDH2 rs671;	—

Countries

China

Contacts

Public ContactZhong Jingquan

Qilu Hospital of Shandong University

18560086597@163.com+86 18560086597

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026